RecruitingNAFLD
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
Eligible age
18–75 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
In this study, semaglutide will be compared to placebo (a look-alike inactive substance, a "sugar pill") to determine if its use will prevent weight gain after liver transplantation (LT). In addition, researchers will be testing to determine if semaglutide prevents the development of Non-Alcoholic Fatty Liver Disease (NAFLD) after transplant through Magnetic Resonance Imaging (MRI) and laboratory results.
Sponsor: University of Virginia
You may qualify if…
- ✓ Male or female age 18-75 years who received LT for any indication (i.e. NASH, hepatitis C, alcohol-induced cirrhosis, autoimmune hepatitis, etc.)
- ✓ Liver transplant surgery within 8-24 weeks prior to randomization
- ✓ Fasting glucose \> 125 mg/dL or presence of diabetes (HbA1c≥6.5% or use of diabetes medications) or pre-diabetes (HbA1c \>5.7%)
- ✓ Ability to provide informed consent
- ✓ Discharged from the hospital following LT surgery
- ✓ Tolerating diet
- ✓ Normal graft function\* (determined by treating hepatologist/surgeon based on clinical status and hepatic panel)
- ✓ Stable immunosuppression according the VCU (Virginia Commonwealth University) post-LT protocols \*\* (i.e. calcineurin inhibitors + mycophenolate)
You may not qualify if…
- ✕ BMI≤ 27kg/m2
- ✕ GFR (Glomerular Filtration Rate) ≤ 25 ml/min/1.73m2
- ✕ Type 1 autoimmune diabetes (by anti-GAD (glutamic acid decarboxylase) or history of ketoacidosis)
- ✕ History of gastroparesis
- ✕ Familial or personal history of medullary thyroid cancer or MEN (Multiple Endocrine Neoplasia) 2
- ✕ History of pancreatitis
- ✕ History of active malignancy post- LT with the exception of non-melanoma skin cancers
- ✕ History of uncontrolled or unstable diabetic retinopathy or maculopathy
Where it's recruiting
Virginia
Richmond
Source: ClinicalTrials.gov · NCT05424003 · last updated 2026-06-04